Relapsed Adult ALL
7 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (NCT03938987) | University of Alberta | 2021-03-03 |
| Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT (NCT04516551) | Xinqiao Hospital of Chongqing | 2020-11-20 |
| CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (NCT03774654) | Baylor College of Medicine | 2020-04-14 |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) (NCT03091933) | Ciusss de L'Est de l'Île de Montréal | 2017-02-06 |
Track Relapsed Adult ALL automatically
Every clearance here is in the API, with alerts when new ones post.